[Asia Economy Reporter Yoo Hyun-seok] NewG Lab is showing strong performance. It appears that the analysis from securities firms, which noted that the metabolic anticancer drug KAT is currently in preclinical stages and plans to submit an Investigational New Drug (IND) application targeting liver cancer and solid tumors by the end of this year, has had an impact.
As of 10:05 AM on the 8th, NewG Lab was trading at 13,300 KRW, up 3.91% (500 KRW) compared to the previous trading day.
NewG Lab is a company developing the metabolic anticancer drug ‘KAT.’ It is a therapeutic agent that blocks the metabolism (energy production) of cancer cells using a substance called 3BP. KAT is currently in the preclinical stage. It has already received orphan drug designation from the U.S. Food and Drug Administration (FDA) for liver cancer and cholangiocarcinoma.
Researcher Oh Byung-yong from Hanyang Securities explained, "Currently, Dr. Ko Young-hee serves as co-CEO and CSO of NewG Lab’s U.S. branch, and Dr. Pedersen is also serving as a scientific advisory board member of NewG Lab. Although the somatic mutation theory has overshadowed the metabolic theory and metabolism-based anticancer drugs are not yet mainstream, the mainstream will eventually change. In the long term, KAT holds a history and story that can generate great public expectations when the metabolic theory becomes mainstream."
He added, "KAT is currently in preclinical stages and plans to submit an IND application targeting liver cancer and solid tumors by the end of this year. Unlike existing targeted therapies, metabolic anticancer drugs have the significant advantage of being widely applicable to all solid tumors."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
